Please login to the form below

Not currently logged in
Email:
Password:

Thomas Shenk leaves Merck board to focus on forthcoming antiviral company

Aims to commercialise research work carried out at Princeton University

Thomas Shenk - formerly of MerckThomas Shenk has retired from Merck & Co's board of directors after 11 years.

He has left to focus on a new business build on his work with Princeton University, where he has been Elkins Professor in the department of molecular biology since 1984 and served as chairman of the department from 1996 to 2004.

His forthcoming company will aim to commercialise discoveries in the field of antiviral therapy made at his Princeton laboratory.

Shenk's research includes work with fellow academic Ileana Cristea to research sirtuins – enzymes that can stem viral infections.

The broad antiviral activity of sirtuins indicates they can be used to treat a number of viral diseases.

A provisional patent application has been filed by Shenk and Cristea on known sirtuin agonists and several dual antagonists as broad spectrum antiviral therapeutics.

Shenk is also director of the Fox Chase Cancer Center – a Philadelphia-based hospital specialising in the treatment, research and prevention of cancer – and editor-in-chief for The Journal of Virology.

10th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics